Eric Johnston, chief equity and macro strategist at Cantor Fitzgerald, said he believes stocks are in for a tactical ...
The financial services giant Cantor Fitzgerald is predicting the stock market will see rallies in the next one to two weeks.
Cantor Fitzgerald has a “Overweight” rating and a $11.00 price objective on the stock. The consensus estimate for Codexis’ current full-year earnings is ($0.77) per share. Get Codexis alerts: ...
On Friday, Cantor Fitzgerald initiated coverage on Protara Therapeutics (NASDAQ:TARA) with an Overweight rating, indicating a positive outlook for the biopharmaceutical company’s stock.
Exagen Inc. (NASDAQ:XGN – Free Report) – Stock analysts at Cantor Fitzgerald increased their FY2024 EPS estimates for Exagen in a research note issued to investors on Monday, March 10th.
In a report released yesterday, Andres Sheppard from Cantor Fitzgerald initiated coverage with a Buy rating on Eve Holding (EVEX – Research Report) and a price target of $5.00. The company’s ...